- Home
- LAB vs ADPT Comparison
LAB vs ADPT Comparison
Compare LAB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- ADPT
- Stock Information
- Founded
- LAB 1999
- ADPT 2009
- Country
- LAB United States
- ADPT United States
- Employees
- LAB N/A
- ADPT 709
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAB Industrials
- ADPT Health Care
- Exchange
- LAB Nasdaq
- ADPT Nasdaq
- Market Cap
- LAB 642.1M
- ADPT 749.7M
- IPO Year
- LAB 2011
- ADPT 2019
- Fundamental
- Price
- LAB $1.58
- ADPT $5.08
- Analyst Decision
- LAB Strong Buy
- ADPT Buy
- Analyst Count
- LAB 2
- ADPT 4
- Target Price
- LAB $2.88
- ADPT $6.50
- AVG Volume (30 Days)
- LAB 2.5M
- ADPT 1.1M
- Earning Date
- LAB 10-30-2024
- ADPT 11-07-2024
- Dividend Yield
- LAB N/A
- ADPT N/A
- EPS Growth
- LAB N/A
- ADPT N/A
- EPS
- LAB N/A
- ADPT N/A
- Revenue
- LAB $155,902,000.00
- ADPT $177,282,000.00
- Revenue This Year
- LAB $62.60
- ADPT $3.82
- Revenue Next Year
- LAB $9.91
- ADPT $20.38
- P/E Ratio
- LAB N/A
- ADPT N/A
- Revenue Growth
- LAB 48.23
- ADPT N/A
- 52 Week Low
- LAB $1.21
- ADPT $2.28
- 52 Week High
- LAB $3.04
- ADPT $6.70
- Technical
- Relative Strength Index (RSI)
- LAB 34.81
- ADPT 47.04
- Support Level
- LAB $2.12
- ADPT $5.09
- Resistance Level
- LAB $2.26
- ADPT $6.70
- Average True Range (ATR)
- LAB 0.17
- ADPT 0.46
- MACD
- LAB -0.04
- ADPT 0.00
- Stochastic Oscillator
- LAB 1.33
- ADPT 24.48
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).